Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myeloid, Acute 196Myelodysplastic Syndromes 128Precursor Cell Lymphoblastic Leukemia-Lymphoma 123Leukemia, Lymphocytic, Chronic, B-Cell 102Leukemia 102Lymphoma 86Multiple Myeloma 81Lymphoma, Non-Hodgkin 80Hematologic Neoplasms 65Leukemia, Myelogenous, Chronic, BCR-ABL Positive 62Hodgkin Disease 62Recurrence 52Lymphoma, B-Cell 40Lymphoma, Mantle-Cell 39Myeloproliferative Disorders 36Lymphoma, Follicular 35Melanoma 34Lymphoma, Large B-Cell, Diffuse 31Burkitt Lymphoma 31Graft vs Host Disease 28Neoplasms, Plasma Cell 24Primary Myelofibrosis 23Ovarian Neoplasms 23Lymphoma, B-Cell, Marginal Zone 23Anemia, Refractory, with Excess of Blasts 21Leukemia, Myelomonocytic, Chronic 20Leukemia, Biphenotypic, Acute 17Lymphoma, T-Cell 16Neuroblastoma 15Neoplasms 14

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Non-Malignant Neoplasm × fludarabine × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡